Note: This document contains side effect information about insulin lispro. Some of the dosage forms listed on this page may not apply to the brand name Humalog.
Applies to insulin lispro: suspension
Along with its needed effects, insulin lispro (the active ingredient contained in Humalog) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking insulin lispro:
Incidence not known
Some side effects of insulin lispro may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to insulin lispro: injectable solution, subcutaneous solution
Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.
Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
Very common (10% or more): Hypoglycemia
Frequency not reported: Weight gain
Frequency not reported: Allergic reactions including anaphylaxis
Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.
Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, pruritus (with or without rash) was seen in 17 patients receiving human insulin (n=2969) and 30 patients receiving insulin lispro (n=2944).
Common (1% to 10%): Infusion site reactions
Rare (less than 0.1%): Catheter occlusions/month
Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.
Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy
Very common (10% or more): Headache (up to 29.6%)
Rare (less than 0.1%): Painful peripheral neuropathy
Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.
The clinical significance of the development of these antibody titers is unknown.
Very common (10% or more): Flu syndrome (up to 34.6%), infection (up to 13.6%)
Frequency not reported: Anti-insulin antibody titers
Frequency not reported: Peripheral edema
Insulin may cause sodium retention and edema, especially as metabolic control is improving.
Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.
Uncommon (0.1% to 1%): Urticaria, rash
Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy
Common (1% to 10%): Nausea, diarrhea, abdominal pain
Common (1% to 10%): Urinary tract infection, dysmenorrhea
Common (1% to 10%): Myalgia
Very common (10% or more): Pain (up to 19.8%)
Common (1% to 10%): Fever
Very common (10% or more): Pharyngitis (up to 33.3%), rhinitis (up to 24.7%), increased cough (up to 17.3%)
Common (1% to 10%): Sinusitis, bronchitis
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Humalog Kwikpen